Synthesizing Therapeutics...

ASD Drug Discovery

Innovations in ASD Drug Discovery: Overcoming Challenges and Shaping Future Perspectives
Biomedical & Pharmacology Monograph Catalog LP-MC-005

Innovations in ASD Drug Discovery: Overcoming Challenges and Shaping Future Perspectives

A translational roadmap into rational autism therapeutics—spanning convergent neurobiology, iPSC cerebral organoids, CRISPR perturbations, directed evolution, and biomarker-guided clinical trials.

Authors: Peter De Ceuster & Shella MaDisciplines: Translational Psychiatry · CRISPR · OrganoidsFocus: Core ASD Symptom TherapeuticsSeries: Companions Vol. V of The Rising Sea

Discovery

Cover Plate

Mapping the biological convergence of high-confidence ASD risk pathways toward druggable synaptic and metabolic targets.

Unmet Needs

Moving beyond comorbid symptom management to address core social communication and excitatory-inhibitory signaling imbalance.

iPSC Organoids

Patient-derived 3D cortical organoids revealing early neurodevelopmental trajectories unreachable in standard rodent assays.

CRISPR & Evolution

High-throughput Perturb-seq screens and directed evolution engineering precision biologics with cleaner receptor selectivity.

Blood-Brain Barrier

Receptor-mediated transcytosis, nanoparticle shuttles, and intranasal peptide delivery overcoming CNS bioavailability walls.

Adaptive Trials

Biomarker stratification (EEG signatures, metabolomic cohorts, digital phenotyping) rescuing heterogeneous clinical cohorts.

Precision

Chapter 1–3 · Pathophysiology & Unmet Needs

Deconstructs why legacy trial designs failed heterogeneous ASD cohorts and pinpoints convergent mTOR, chromatin, and GABA/glutamate nodes.

Chapter 4–6 · Preclinical Revolution

Patient-specific human cortical organoids, single-cell transcriptomics, and multiplex CRISPR screening pipelines.

Chapter 7–9 · Precision Modalities

Small-molecule allosteric modulators, antisense oligonucleotides, directed-evolution biologics, and CNS delivery vectors.

Chapter 10–12 · Quantitative Trial Design

Integrating circadian SCN biomarkers and stratified endpoints into ethically grounded regulatory pathways.

From the Monograph · Rational Therapeutics

“Accelerating progress in uncovering genetic and neurobiological convergence across Autism Spectrum Disorder finally gives medicinal chemistry a coherent map—transforming fragmented trials into biomarker-stratified precision pharmacology.”